Introduction
Multiple valve disease is increasingly prevalent and choosing the appropriate treatment strategy may pose challenges to the clinician. Moderate-to-severe mitral regurgitation (MR) is present in about 20% of elderly patients with severe aortic stenosis (AS), 1 with a reported prevalence varying from 3 to 74% among different studies, 2 and is associated with higher mortality after both surgical aortic valve replacement (SAVR) 3 and transcatheter aortic valve replacement (TAVR) in particular when MR persists post-interventionally. 4 In addition, some patients may present with concomitant tricuspid regurgitation (TR), 5 which is a sign of advanced disease and a predictor of increased mortality after SAVR 6 and TAVR. 7 Whilst double valve surgery corrects both lesions, operative mortality is twice that of isolated AVR. 8, 9 Due to the associated afterload reduction, regression of MR severity may be observed in 50-70% of patients undergoing isolated SAVR and 50% of patients undergoing isolated TAVR. the remaining patients. A pragmatic therapeutic approach for concomitant MR in severe AS has been suggested, taking into account MR severity, aetiology as well as the procedural risk. 10 However, both the European Society of Cardiology/European Association for CardioThoracic Surgery and the American College of Cardiology/American Heart Association guidelines on valve disease conclude that there is paucity of data on the natural history on mixed and multiple valve disease which does not allow for evidence-based recommendations. 11, 12 The aim of the present study was therefore to assess the outcome of patients with severe AS and concomitant MR and TR with particular consideration of the impact of the respective treatment approaches so as to optimize the management of these patients.
Methods

Patient population
The process of patient enrolment and the study flow is illustrated in Figure 1 . All consecutive patients who were studied in our outpatient heart valve clinic (HVC) between 1999 and 2012 and who were found to have a combination of severe AS with at least moderate MR were included into the study. Exclusion criteria were previous cardiac surgery or additional hemodynamically significant valve lesions (moderate or severe) except for TR. According to these criteria, 89 consecutive patients (66 female) were identified. According to the purely observational study design, written informed consent was not demanded. The study protocol was approved by the ethics committee of the Medical University of Vienna.
Clinical data
At study entry, a comprehensive baseline assessment was performed that included medical history, assessment of current medication, physical examination, electrocardiogram, blood tests, and transthoracic echocardiography.
The following data were collected: age, sex, body mass index, and body surface area; the patient's symptomatic status; presence of comorbidities: coronary artery disease (history of myocardial infarction, angioplasty, coronary artery bypass graft (CABG), or angiographically documented coronary artery stenosis) chronic obstructive pulmonary disease (long-term use of bronchodilators or use of steroids for lung disease), arterial hypertension (blood pressure > _140/90 mmHg at repeated measurements; or use of antihypertensive agents), atrial fibrillation (AF) (present on the electrocardiogram at baseline or verified episode of AF within the last 6 months), hypercholesterolemia (total serum cholesterol > _240 mg/dL or cholesterol-lowering medication), and diabetes (fasting blood glucose level >126 mg/dL or use of antidiabetic medication).
Echocardiographic data
Echocardiography was performed using commercially available ultrasound systems. All patients underwent a comprehensive examination including M-Mode, 2D echocardiography, conventional, and colour Doppler by an experienced echocardiographer. Apical four-chamber and two-chamber views were used for calculation of ventricular volumes and ejection fraction by Simpson's biplane formula. A left ventricular ejection fraction (LVEF) > _60% was considered normal, a LVEF of 40-60% was considered mildly depressed, a LVEF of 30-40% moderately depressed, and a LVEF of <30% severely depressed. Right ventricular function was assessed both visually and based on tricuspid annular plane systolic excursion and Doppler tissue imaging as recommended 13 and graded as normal, mildly, or severely depressed.
Multiple transducer positions were used to record peak aortic jet velocities and aortic valve area was calculated using the continuity equation.
14 Severe AS was defined by an aortic valve area < _1 cm 2 and an aortic velocity > _ 4 m/s in the presence of normal flow. In patients with low flow gradient AS, the severity of AS was confirmed by dobutamine echocardiography 15 and by the presence of extensive aortic valve calcification. 16, 17 In the quantification of lesion severity, potential interactions of coexisting lesions on the respective parameters were considered. 10 An integrated approach including qualitative, quantitative, and semiquantitative parameters was used for the quantification of MR as proposed by current recommendations. 18, 19 The assessment included valve morphology, LV volume load, proximal regurgitant jet width, proximal flow convergence, and pulmonary venous flow pattern. LV diameters and ejection fraction, as well as systolic pulmonary artery pressure (using tricuspid regurgitant velocity), were measured as recommended.
20
TR was quantified by an integrated approach. 18 Echocardiographic parameters used for grading included TV morphology, vena contracta width; proximal flow convergence radius and hepatic venous flow pattern. RV, right atrial, and inferior vena cava diameters were also considered. Post-procedural evaluation of prosthetic valves was performed as recommended. 21 
Follow-up
Patients were followed prospectively after their initial visit at the HVC. Asymptomatic patients were scheduled to undergo follow-up exams every 6 months based on a watchful waiting approach, and were referred to surgery once they had reached an indication for surgery. 11, 12 Patients who underwent valve procedures had a post-procedural follow-up visit 6-12 months after the intervention in the HVC to assess the surgical outcome. Further post-operative follow-up exams in the HVC were scheduled at extended intervals, depending on surgical and clinical outcomes. Follow-up information was obtained from interviews with the patients, their relatives and their physicians. Information regarding the development of cardiac symptoms, valve intervention, and death was obtained.
Exercise testing was performed at clinical discretion in apparently asymptomatic patients. For the assessment of outcome, overall survival (i.e. time from study entry to death from any cause) was assessed.
Choice of procedure
In the presence of an indication for intervention, a comprehensive workup (including coronary angiography, carotid ultrasound, spirometry, and aortic CT-angiography in selected patients) was performed, and cases were discussed in a heart team consisting of cardiac surgeons as well as invasive and non-invasive cardiologists. Treatment decisions were individualized considering the patient's risk profile, comorbidities, age and preferences as well as the severity and aetiology of MR and the severity of TR. 22 
Statistical analysis
Categorical baseline variables are described as counts and percentages and compared between groups using v 2 tests. Continuous baseline variables are described as medians and quartiles and compared between groups using Wilcoxon rank-sum tests and Kruskal-Wallis tests due to skewed distributions. Median follow-up is calculated using the inverse Kaplan-Meier method. 23 Survival rates [with 95% confidence intervals (CIs)] at clinically relevant time points and median survival (with quartiles) are deduced from the Kaplan-Meier estimates.
For graphically comparing patients undergoing valve procedures with those managed conservatively, Kaplan-Meier survival estimates are displayed for a landmark of 4 months after inclusion into the study in order to account for the time-dependence of the factor 'valve procedure'. Patients censored or died before 4 months are excluded in Figure 2 . A Cox regression model with time-dependent valve procedure factor is used to calculate a hazard ratio (HR) with 95% CI adjusted for EuroSCORE II.
Post-interventional survival is compared between groups defined at or before surgery using Kaplan-Meier estimates and a log-rank test. In a Cox regression model an adjustment for baseline EuroSCORE II is accomplished by inverse probability weighting using a propensity score based on EuroSCORE II. The propensity score of a patient is defined as the probability to receive the treatment under investigation conditional on pre-treatment covariates. 24 Each patient's contribution is weighted by the inverse of this probability if treated with this treatment under investigation and by the inverse of one minus this probability otherwise. The potential influence of baseline TR is investigated in a Cox regression model adjusting for EuroSCORE II and time-dependent effects of surgery and (nested) tricuspid valve surgery.
The reported P-values are the results of two-sided tests. P-values < _0.05 are considered to be statistically significant. All computations were carried out using SAS software Version 9.4 (SAS Institute Inc., Cary, NC, USA, 2012).
Results
Baseline patient characteristics are given in Table 1 . Patients addressed for severe AS and concomitant MR were relatively old (median 80 years, quartiles 75-84), had relevant comorbidities and consequently a high operative risk as reflected in the median EuroSCORE II of 7.1% (quartiles 4.5-10.9). At baseline, 36 patients presented with moderate MR and 53 patients with severe MR. LVEF was abnormal in 36 patients: 15 patients had mildly reduced LVEF and 21 had at least moderately reduced LVEF (<40%). Severe low-flow low-gradient AS confirmed by dobutamine stress-echocardiography was present in five patients while the other patients had high transaortic gradients despite a reduced LVEF. In addition, 36 patients had concomitant moderateto-severe TR.
Mechanisms of MR
Seventy-two (81%) patients had secondary MR and 17 (19%) patients had primary MR. Of the latter, 10 had mitral valve prolapse, six had a flail leaflet and one patient had rheumatic mitral valve disease with severe MR and mild mitral stenosis. Some extent of age-related valve degeneration including thickening of the leaflet tips was present in the majority of patients with secondary MR. patients, 80% (n = 60) were severely symptomatic (New York Heart Association/CCS class > _ 3) and 33% (n = 25) had a history of decompensated heart failure that required urgent inpatient care.
Presentation of patients
Event-free survival of the asymptomatic patients
During a median follow-up of 47.2 (quartiles 27.2-114.4) months, nine of the 14 patients who were asymptomatic at presentation, developed an indication for surgery and 3 patients died (heart failure n = 1, trauma n = 1, and stroke n = 1), respectively.
Indications for valve intervention
During follow-up, 84 patients had indications for surgery for the following reasons: symptoms (n = 60); symptoms and left ventricular dysfunction (n = 21); and asymptomatic left ventricular dysfunction (n = 3).
Valve interventions
Valve procedures were performed in 49 patients: isolated aortic valve intervention in 28 patients (22 SAVR and 7 TAVR), SAVR and tricuspid repair in one patient, SAVR and mitral valve surgery in 9 of 10 (90%) patients with primary MR and in 11 of 39 (28%) patients with secondary MR. Eighteen (90%) of the patients that underwent concomitant mitral surgery had severe MR. Mitral valve repair was performed in 10 of the 20 patients undergoing mitral valve surgery. Post-operatively, MR had improved by 0.7 (0.4-1.0) degrees in patients undergoing isolated AVR and by 2.3 (1.8-2.7) degrees in patients undergoing combined surgery (P < 0.001). No significant change in TR severity was observed whether concomitant mitral valve surgery was performed or not.
Concomitant tricuspid repair was performed in seven patients that underwent SAVR and mitral valve surgery. In 13 patients, concomitant CABG was performed.
Valve interventions were not performed in 35 patients due to the following reasons: patient refusal (n = 16), denial because of high surgical risk (n = 12), death on the waiting list (n = 6), and surgery aborted due to porcelain aorta (n = 1). Patients who were denied surgery were older [83 (quartiles 81-88) vs. 80 (quartiles 75-79.2) years; P = 0.02] but had otherwise comparable clinical characteristics.
Survival
Fifty-three patients died during follow-up and all but four [trauma (two); stroke (one); unknown (one)] of these deaths were of cardiac origin. Overall survival rates for the entire patient population were 73% (95% CI 63-81), 58% (95% CI 46-68), and 34% (95% CI 22-46) at 1, 2, and 5 years, respectively.
Three patients that were previously asymptomatic died 162, 189, and 706 days after their index examination due to acute heart failure (n = 1), trauma (n = 1), and stroke (n = 1).
Of all patients with an indication for AVR who did not refuse surgery six patients died while waiting for valve intervention. These patients presented with one or more of the following characteristics: five presented with severe symptoms, four had a previous episode of cardiac decompensation, four had significant TR and two had a severely depressed systolic LV function. Reasons of death included acute heart failure (n = 5) and sepsis due to a superinfected femoral pseudoaneurysm after pre-operative coronary angiography (n = 1).
15 of 16 patients who had an indication for AVR due to symptoms but refused to undergo valve interventions died due to acute heart failure (n = 12), myocardial infarction (n = 1), sudden death (n = 1), and unknown (n = 1). Median survival for this subgroup of patients was 658 days (quartiles 399-1536). 10 out of 12 patients in whom the heart team recommended a conservative strategy died due to acute heart failure (n = 5), myocardial infarction (n = 2), pneumonia (n = 1), trauma (n = 1), and unknown (n = 1). Median survival for this subgroup was 241 days (quartiles 87-843). In addition, one patient in whom surgery was aborted due to porcelain aorta in the pre-TAVR era died from acute heart failure.
Survival according to management strategy
Survival rates comparing patients undergoing valve intervention with those managed conservatively are displayed for a landmark of 4 months after inclusion into the study (Figure 2) : of all 74 patients still under study at 4 months those already having had valve intervention (23 patients) show higher survival rates when compared with those who had not yet undergone valve intervention (51 patients). The effect of valve interventions also persisted after adjusting for the pre-operative EuroSCORE II (HR = 0.50; P = 0.032).
Post-interventional survival
Eighteen deaths occurred among the 49 patients that had undergone valve interventions. Overall post-procedural survival rates were 81% (95% CI 66-90), 75% (95% CI 59-85), and 57% (95% CI 36-73) at 1, 2, and 5 years, respectively.
There were three periprocedural (within 30 days) and five early post-procedural (1-3 months after the valve procedure) deaths: myocardial infarction (n = 2), haemorrhagic shock (n = 1), sepsis (n = 1), and acute heart failure (n = 1). Ten patients died during late follow-up (n = 10) due to acute heart failure (n = 8), mitral valve endocarditis (n = 1), and myocardial infarction (n = 1).
Post-interventional survival according to interventional strategy
For the graphic presentation of post-interventional survival, patients were subdivided into three groups: patients receiving combined aortic and mitral valve surgery (Group 1), patients with moderate MR at baseline receiving an isolated aortic intervention (Group 2), and patients with severe MR who underwent isolated aortic intervention (Group 3). The baseline characteristics of these groups are given in Table 2 .
Unadjusted post-procedural survival rates at 1, 2, and 5 years, were, 85% (95% CI 60-95), 78% (95% CI 52-91), and 59% (95% CI 18-85), respectively for Group 1; 94% (95% CI 65-99), 85% (95% CI 50-96), and 75% (95% CI 40-92) for Group 2; and 50% (95% CI 18-75), 50% (95% CI 18-75), and 25% (95% CI 4-55) for Group 3 (P = 0.031; Figure 3) . 
Concomitant TR in patients with AS and MR
The presence of moderate-to-severe TR was associated with lower overall survival rates: 45% (95% CI 28-61), 32% (95% CI 17-48), and 12% (95% CI 2-29) at 1, 2, and 5 years, respectively as compared with 92% (95% CI 80-97), 76% (95% CI 60-86), and 49% (95% CI 31-65) at 1, 2, and 5 years, respectively for patients with no or mild TR (adjusted HR = 3.06; 95% CI 1.63-5.75; P < 0.001; Figure 4) . Apart from more pronounced pulmonary hypertension, patients with significant TR had a similar risk profile ( Table 1) .
The presence of significant TR was also associated with early postoperative mortality (moderate-to-severe TR was present in 14 patients undergoing valve interventions and tricuspid surgery was performed in seven of these): the 3-month mortality rate after surgery for the 35 patients being operated with no or mild TR was 3.0% as compared with 51.0% for the 14 patients with moderate-to-severe TR (P < 0.001). Of the latter, three had undergone combined aortic, mitral, and tricuspid surgery, while four had undergone isolated aortic intervention (two of them TAVR).
Discussion
A high-risk population Concomitant significant MR in patients with severe AS characterizes a high-risk population, as reflected by the following findings:
(1) The patients included in this series were mostly high-risk patients (EuroSCORE II: 7.1%) that were old (median age 80 years) and had important comorbidities. It is thus a population at significant operative risk.
(2) Most of these patients already presented with symptoms at their index examination, with the majority being severely symptomatic. Furthermore, one-third of the symptomatic patients already had a history of previous cardiac decompensation that required inpatient care and six symptomatic patients rapidly died before any intervention could be scheduled. (3) Overall survival rates for the entire patient population were 73% (95% CI 63-81), 58% (95% CI 46-68), and 34% (95% CI 22-46) at 1, 2, and 5 years, respectively. In comparison, patients with isolated severe symptomatic AS from an earlier series 25 had significantly better overall survival with rates of 90% (95% CI 86-93%), 85% (95% CI 80-89%), and 70% (95% CI 63-76%) at 1, 2, and 5 years, respectively (P < 0.001). 
Role and timing of valve procedures
Many of the patients did not undergo any valve procedure at all due to patient refusal in 16 patients and denial by the heart team in 12 patients. Patients being denied valve procedures were older but had an otherwise comparable risk profile. Intervention however, when performed, was associated with a survival benefit. The high risk of mortality during workup/on the waiting list for valve procedures [six of 84 (7%) patients with an indication for AVR died while waiting for intervention], further emphasizes the importance of urgent treatment without any delays in this high-risk population. It can be expected that with the advent of transcatheter treatment options, fewer patients may be denied treatment. At the same time, the potential futility of these interventions will need to be considered.
Impact of different treatment strategies
Concomitant mitral surgery was performed in 18 of 28 (64%) patients with severe MR and in 2 of 21 (10%) patients with moderate MR. In the present series, secondary MR was the predominant aetiology (81%). The decisions were taken by the Heart Team based on an individualized approach, considering interventional risks and the expected disease course. In an unadjusted analysis, post-interventional outcomes after AVR were comparable for patients who underwent concomitant mitral valve surgery for severe MR and for patients with concomitant moderate MR that was left untreated, while patients with severe MR who underwent isolated AVR had a high mortality. Importantly, this finding supports the careful integrated approach used to quantify MR in the present study, as emphasized by current guidelines. 27, 28 With propensity score adjustment for the baseline EuroSCORE II, the benefit of concomitant mitral surgery in the presence of severe MR (HR 0.52) did not reach statistical significance but nevertheless, a significant reduction in MR was achieved when compared with patients with isolated aortic intervention. It has been demonstrated previously that moderate or severe MR at baseline was associated with increased 2-year mortality after SAVR but not after TAVR. 29 Nevertheless, in a recent meta-analysis of 8 studies comprising 8927 patients, significant residual MR after TAVR was associated with an increased 1-year mortality after TAVR. 30 Therefore, concomitant mitral valve surgery should be considered, when the incremental surgical risk is acceptable. In the presence of a high surgical risk, isolated aortic valve intervention may nevertheless be associated with a survival benefit. Careful patient assessment, procedural risk stratification and an individualized decision is thus essential. Novel percutaneous treatment approaches might be beneficial for high-risk patients requiring multivalve procedures. 31 
Prognostic value of TR
It is accepted that in patients with severe primary MR, the surgical correction of concomitant significant TR can be performed without significantly increased surgical risk and is associated with good postoperative outcomes. 32 In contrast, the presence of moderate-to-severe TR in patients with AS and MR is a strong independent predictor of increased mortality (HR 3.06) even when adjusting for the baseline EuroSCORE II. Furthermore, in the present series, it was associated with a periprocedural mortality close to 50% as compared with 3% (P < 0.001) for patients without significant TR. Accordingly, a subgroup analysis of the PARTNER II trial 7 demonstrated that moderate or severe TR and right heart enlargement are independently associated with increased 1-year mortality in inoperable patients treated with TAVR. The presence of TR thus indicates more advanced disease stages. 33 In this regard, the present findings suggest that performing valve procedures in patients with severe AS, concomitant MR and significant TR should be carefully balanced against the poor outcome that these patients may experience. It is thus important to recognize severe concomitant TR in the pre-interventional workup and risk assessment.
Study limitations
The proportion of patients with severe AS presenting with concomitant MR is in the lower range of the reported prevalence and might be explained by different referral patterns in the pre-transcatheter treatment era. Higher referral can be expected in the current era. The present study is a purely observational series of consecutive patients and has the inherent limitation of not being a randomized trial regarding treatment choices. Nevertheless, this limitation is compensated for by propensity score matching. Only a limited number of the patients in the present study were treated with TAVR (either because it was decided to perform a surgical multivalvular procedure or due to inclusion in the pre-TAVR era). While this made it possible to more accurately document the natural course of the disease, the precise role of TAVR in the treatment of these patients remains to be established. Serum biomarkers were not routinely assessed in this patient population. The patients included in the present study, however, were mostly severely symptomatic and many of them already had had an episode of decompensated congestive heart failure. Therefore, we believe that assessment of serum biomarkers such as N-terminal pro-B-type natriuretic peptide (NT-proBNP) would not have changed the decision-making process. While a predictive value of neurohormones in AS has been reported, 34 future studies should assess its potential role in the specific population of patients with multivalvular disease. The patient's frailty or immobility was not systematically assessed by a geriatrician and thus might be subject to bias of the attending physician in the valve clinic.
Conclusion
Presence of MR in patients with severe AS characterizes a high-risk population of elderly and mostly severely symptomatic patients. Timely aortic valve intervention confers a survival benefit and concomitant mitral valve surgery should be considered according to operative risk. The additional presence of significant TR is associated with dismal outcomes, regardless of the treatment strategy. 
